Christopher Highley
Family Medicine · Reno, NVNPI 1235191693
Payments from drug & device makers
Across 103 payments — averaging $18.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$312
- AstraZeneca$239
- GSK$230
- AbbVie$220
- Pfizer$193
- Boehringer Ingelheim$106
- plus $625 from 17 others
What the payments were for
- Food & beverage$1,90699%
- Education$191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 21 | $312 |
| AstraZeneca | 13 | $239 |
| GSK | 14 | $230 |
| AbbVie | 12 | $220 |
| Pfizer | 6 | $193 |
| Boehringer Ingelheim | 6 | $106 |
| Novartis | 4 | $97 |
| Lilly USA, LLC | 5 | $91 |
| Tactile Systems Technology Inc | 3 | $54 |
| Exact Sciences | 3 | $51 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $43 |
| Merck | 2 | $41 |
| Antares Pharma, Inc. | 1 | $33 |
| Inspire Medical Systems, Inc. | 1 | $32 |
| Vertex | 1 | $31 |
| Supernus Pharmaceuticals, Inc. | 2 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Dexcom, Inc. | 1 | $18 |
| Eisai Inc. | 1 | $17 |
| Acerus Pharmaceuticals Corporation | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
How this compares
$1,925 in reported general payments places this provider in the 75th percentile of 902 family medicine providers in Nevada.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 38 | $29,064 |
| Repatha SureclickEvolocumab | 28 | $22,813 |
| TrulicityDulaglutide | 23 | $21,223 |
| Pregabalin | 39 | $1,517 |
| Eszopiclone | 18 | $1,080 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 28 | $1,017 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 25 | $712 |
| Levothyroxine Sodium | 69 | $497 |
| Carvedilol | 18 | $413 |
| Ipratropium Bromide | 22 | $394 |
| Alprazolam | 59 | $385 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 19 | $381 |
| Allopurinol | 31 | $371 |
| Amlodipine Besylate | 49 | $370 |
| Celecoxib | 11 | $358 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $193 | $29,06438 claims |
| Lilly USA, LLCTrulicity | $91 | $21,22323 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 902 family medicine providers in Nevada.
Other family medicine in Reno
- Susan ParkReno$1.1M
- Bayo Curry-WinchellReno$74K
- Catherine McCarthyReno$68K
- Francisco DofelizReno$30K
- Michael ObrienReno$18K
- James McLennanReno$16K
- Jeremy BearfieldReno$15K
- Ricardo GonzalezReno$11K
- Jennifer HornbackReno$11K
- Ambika UppuReno$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.